With two API manufacturing units, MPL has successfully captured the value chain and moved closer to the vision of becoming a fully integrated company globally.

The two API plants are situated near Kurkumbh in Pune. Various Bulk Drugs & Intermediates are manufactured at these locations.

The plants started with a production capacity of 36 TPA and expanded its existing capacity of Quinolones from 250 TPA to 600 TPA and multi purpose bulk drug unit with capacity of 180 TPA.

The present manufacturing capacity of 1140 TPA (600 TPA Quinolones, 360 TPA Ranitidine, and 180 Others) is sufficient to equate this company with other major bulk drug players in India. The company has established itself in the local market as well as export market with supplies to more than 54 countries.

Since its conception MPL has gradually built its own identity as an API and intermediates supplier in domestic as well as international markets. The manufacturing facility is well supported by a state of the art contained plants for the purpose of scaling up of the process. Leveraging on the in house expertise and in house research company has concentrated on manufacture of Bulk Drugs and Active Pharmaceutical Ingredients that demand technological expertise.

It has embarked on ambitious expansion projects to scale up its existing capacity, to enter new therapeutic segments covering high growth lifestyle-related diseases and to be present over the entire value chain of the drug discovery and development process.

Marksans is the Second Largest producers of Ciprofloxacin and Ranitidine in India. Key focus areas are Cardiovasculars, Antidiabetics and Neurosciences.

The company has embarked on an expansion plan -which will double the annual capacity of its flagship product Ciprofloxacin from 600 MT to 1000 MT and for Ranitidine from 360 MT to 600 MT - which will not only enable it to emerge as their lowest cost manufacturer but also the largest manufacturer of Ciprofloxacin and among the largest makers of Ranitidine in India.

Marksans has various machineries and equipments required to handle various type of synthetic reactions, to produce various bulk drugs such as SS Reactors ranging from 50 to 8000 liters capacity, Glass line reactors from 50 to 8000 liters, MS Reactors from 1000 to 8000 liters, SS and rubber lined centrifuges, steam and electric tray dryers, steam and electric fluid and bed dryers (FBD), various types of filters.

The company has emerged as a dependable provider of APIs which has given it a 'supplier of choice' status for pharmaceutical companies which it intends to leverage and supply to more generic manufacturers globally.

The company has invested in balancing systems to reduce process costs and enhance product quality.

The company intends to leverage its existing client relationships with generic companies to increase outsourcing. The company possesses the ability to handle large production volumes in specific product categories, to manage multi-product plants, to manage production of products belonging to popular segments in intense competitive scenarios in the worst of times, to spot future product winners and to create a robust back-end to manufacture them.

The company will continue to leverage a stringent adherence to CGMP standards, compliance to regulations, quality standards and an on-time delivery commitment to pursue contract-manufacturing opportunities with facilities dedicated for global generics players.